[go: up one dir, main page]

NO20072409L - Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser - Google Patents

Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser

Info

Publication number
NO20072409L
NO20072409L NO20072409A NO20072409A NO20072409L NO 20072409 L NO20072409 L NO 20072409L NO 20072409 A NO20072409 A NO 20072409A NO 20072409 A NO20072409 A NO 20072409A NO 20072409 L NO20072409 L NO 20072409L
Authority
NO
Norway
Prior art keywords
group
alkoxy
alkyl group
hydroxy
alkyl
Prior art date
Application number
NO20072409A
Other languages
English (en)
Inventor
Tadashi Inoue
Satoshi Nagayama
Kazunari Nakao
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072409(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO20072409L publication Critical patent/NO20072409L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)

Abstract

Det beskrives en forbindelse av formel (I) hvor R1 representer en (CrC6)alkylgruppe; R2 representer et hydrogenatom, et halogenatom, en hydroksygruppe, en (Ci-C6) alkylgruppe eller en (CrC6) alkoksygruppe; R3, R4, R5 og R6 representerer hver uavhengig et hydrogenatom, en (Ci-C6) alkyl, eller et halogenatom; R7 representer et hydrogenatom, et halogenatom, en hydroksygruppe, en (CrC6) alkylgruppe valgfritt substituert med en piperidinogruppe, en (Ci-C6)alkoksygruppe valgfritt substituert med en 3-7-leddet sykloalkylring, en hydroksy(CrC6)alkoksygruppe, en (Ci-C6)alkoksy-(Ci-C6)alkylgruppe, en (Ci-C6)alkoksy-(Ci-C6)alkoksygruppe, en halo (Ci-C6)alkylgruppe, en (CrC6)alkyltiogruppe, en (Ci-C6)alkylsulfinylgruppe eller en (CrC6)alkylsulfonylgruppe; R8 representer en (Ci-C6)alkylgruppe, en halo(Cr C6)alkylgruppe, en (CrC6)alkoksygruppe, en hydroksy(Ci-C6)alkoksygruppe, en (Cr C6)alkoksy-(Ci-C6)alkylgruppe eller en (Ci-C6)alkoksy-(Ci-C6)alkoksygruppe; eller R7 og R8, idet de er tilgrensende til hverandre, sammen med karbonatomene hvortil de er festet danner en 5-8-leddet karbosyklisk eller heterosyklisk ring, hvor den karbosykliske ring eller den heterosykliske ring er usubstituert eller substituert med én eller flere substituenter valgt blant gruppen omfattende en hydroksygruppe, en (Ci-C6)alkylgruppe, en (Ci-C6)alkoksygruppe og en hydroksy(CrC6)alkylgruppe; og R9 representer et hydrogenatom eller et halogenatom; eller et farmasøytisk akseptabelt salt eller solvat derav. Disse forbindelser er nyttige for behandling av sykdomstilstander forårsaket av overaktivering av VR1 reseptor, så som smerte eller lignende i et pattedyr. Det beskrives også farmasøytiske materialer omfattende forbindelsen av formel (I).
NO20072409A 2004-11-10 2007-05-09 Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser NO20072409L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62655904P 2004-11-10 2004-11-10
US66097805P 2005-03-10 2005-03-10
US69980105P 2005-07-15 2005-07-15
PCT/IB2005/003321 WO2006051378A1 (en) 2004-11-10 2005-10-31 Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds

Publications (1)

Publication Number Publication Date
NO20072409L true NO20072409L (no) 2007-06-11

Family

ID=35457662

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072409A NO20072409L (no) 2004-11-10 2007-05-09 Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser

Country Status (23)

Country Link
EP (1) EP1824837B1 (no)
JP (1) JP4799562B2 (no)
KR (1) KR20070085957A (no)
AR (1) AR051952A1 (no)
AT (1) ATE404546T1 (no)
AU (1) AU2005303492A1 (no)
BR (1) BRPI0517740A (no)
CA (1) CA2587149C (no)
DE (1) DE602005009017D1 (no)
EA (1) EA200701035A1 (no)
ES (1) ES2308562T3 (no)
GT (1) GT200500323A (no)
IL (1) IL183043A0 (no)
MA (1) MA29012B1 (no)
MX (1) MX2007005709A (no)
NL (1) NL1030382C2 (no)
NO (1) NO20072409L (no)
PA (1) PA8652301A1 (no)
PE (1) PE20061049A1 (no)
TN (1) TNSN07178A1 (no)
TW (1) TW200621694A (no)
UY (1) UY29197A1 (no)
WO (1) WO2006051378A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857440A1 (en) * 2006-04-19 2007-11-21 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2008007211A1 (en) 2006-07-11 2008-01-17 Pfizer Japan Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
ATE478847T1 (de) 2006-09-15 2010-09-15 Pfizer Substituierte pyridylmethylbicyclocarboxyamidverbindungen
ATE520651T1 (de) 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CN101925575B (zh) 2008-01-28 2014-06-18 株式会社爱茉莉太平洋 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
WO2010002209A2 (en) 2008-07-02 2010-01-07 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
CR20180412A (es) 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
TW201343629A (zh) * 2012-01-31 2013-11-01 Lilly Co Eli 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物
KR102599958B1 (ko) * 2016-09-28 2023-11-09 (주)아모레퍼시픽 (r)-n-[4-(1-아미노-에틸)-2,6-다이플루오로-페닐]-메테인설폰아마이드의 제조방법
EP3666254B1 (en) 2017-08-11 2024-12-04 Amorepacific Corporation Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311478B1 (en) * 2000-08-21 2006-06-07 Pacific Corporation Novel (thio)urea compounds and the pharmaceutical compositions containing the same
EP1303483B1 (en) * 2000-08-21 2008-04-23 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
JP2003192660A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
KR100556158B1 (ko) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물

Also Published As

Publication number Publication date
NL1030382C2 (nl) 2006-11-21
TNSN07178A1 (fr) 2008-11-21
ATE404546T1 (de) 2008-08-15
JP2008519817A (ja) 2008-06-12
JP4799562B2 (ja) 2011-10-26
GT200500323A (es) 2006-09-11
EA200701035A1 (ru) 2007-10-26
EP1824837A1 (en) 2007-08-29
UY29197A1 (es) 2006-06-30
TW200621694A (en) 2006-07-01
NL1030382A1 (nl) 2006-05-11
AR051952A1 (es) 2007-02-21
CA2587149A1 (en) 2006-05-18
WO2006051378A1 (en) 2006-05-18
PA8652301A1 (es) 2006-09-22
AU2005303492A1 (en) 2006-05-18
CA2587149C (en) 2010-02-02
PE20061049A1 (es) 2006-10-26
KR20070085957A (ko) 2007-08-27
MA29012B1 (fr) 2007-11-01
IL183043A0 (en) 2007-09-20
DE602005009017D1 (de) 2008-09-25
BRPI0517740A (pt) 2008-10-21
EP1824837B1 (en) 2008-08-13
MX2007005709A (es) 2007-07-09
ES2308562T3 (es) 2008-12-01

Similar Documents

Publication Publication Date Title
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
NO20064366L (no) Tiazolderivat
CY1118879T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
NO20062370L (no) Amidderivater
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
NO20063446L (no) Tiazolderivater
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
NO20054952L (no) 2,3,6-trisubstituerte 4-pyrimidonderivater
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
CR10034A (es) Derivados de oxadiazol
NO20084338L (no) Neurogenesis fremkaller eller terapeutisk neuropatimiddel omfattende alkyl eter derivater eller salter derav
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20081220L (no) Nytt cercosporamidderivat
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
BRPI0511581A (pt) derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application